News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Janssen Announces Data from Simeprevir in Hepatitis C Patients Will be Presented at the International Liver Congress of the European Association for the Study of the Liver (EASL)


4/8/2013 6:16:23 AM

CORK, Ireland, April 8, 2013 /PRNewswire/ --Janssen R&D Ireland (Janssen) announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of hepatitis C at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), which will take place April 24 to 28 in Amsterdam, The Netherlands. These data presentations will include primary efficacy and safety results from the Phase 3 QUEST-1 study of simeprevir administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients.

Read at PR Newswire

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES